Avacta Group (LON:AVCT) Stock Price Down 14.6% - Here's Why

Avacta Group Plc (LON:AVCT - Get Free Report)'s share price dropped 14.6% during trading on Wednesday . The company traded as low as GBX 66.40 and last traded at GBX 67.50. Approximately 4,507,580 shares changed hands during mid-day trading, an increase of 100% from the average daily volume of 2,250,242 shares. The stock had previously closed at GBX 79.Wall Street Analyst Weigh InSeparately, Peel Hunt restated a "buy" rating and set a GBX 99 price objective on shares of Avacta Group in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of GBX 99.View Our Latest Research Report on AVCTAvacta Group Price PerformanceThe company has a market capitalization of £304.87 million, a PE ratio of -4.01 and a beta of 1.12. The company has a debt-to-equity ratio of 52.53, a quick ratio of 4.96 and a current ratio of 1.29. The stock has a 50 day moving average price of GBX 73.83 and a two-hundred day moving average price of GBX 54.95. Avacta Group (LON:AVCT - Get Free Report) last released its quarterly earnings data on Tuesday, September 30th. The biotechnology company reported GBX (4.46) EPS for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. Equities analysts forecast that Avacta Group Plc will post -9.9011833 earnings per share for the current year. Avacta Group Company Profile (Get Free Report)Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).Further ReadingFive stocks we like better than Avacta GroupHow to Invest in Tech Stocks and Top Tech Stocks to ConsiderWhy Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy5 Top Rated Dividend Stocks to ConsiderRTX Surges to Record Highs as Defense Orders ExplodeHow to Effectively Use the MarketBeat Ratings ScreenerSmart Money Is Buying Auto Suppliers, Not Car BrandsThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Avacta Group Right Now?Before you consider Avacta Group, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avacta Group wasn't on the list.While Avacta Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here